LivaNova (NASDAQ:LIVN) Upgraded by StockNews.com to Strong-Buy Rating

LivaNova (NASDAQ:LIVN) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Friday.

Several other brokerages have also commented on LIVN. Stifel Nicolaus increased their price target on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Robert W. Baird increased their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Thursday, October 31st. Mizuho dropped their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Finally, Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $69.17.

LivaNova Stock Down 0.7 %

Shares of LIVN stock traded down $0.35 during trading hours on Friday, reaching $51.63. 341,476 shares of the stock were exchanged, compared to its average volume of 621,525. The business’s fifty day moving average is $51.37 and its two-hundred day moving average is $53.05. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.47. The firm has a market capitalization of $2.80 billion, a P/E ratio of 122.93 and a beta of 1.01.

Institutional Investors Weigh In On LivaNova

Several large investors have recently modified their holdings of LIVN. BNP Paribas Financial Markets boosted its holdings in shares of LivaNova by 88.6% in the first quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock valued at $2,356,000 after acquiring an additional 19,783 shares during the period. Texas Permanent School Fund Corp lifted its holdings in shares of LivaNova by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 47,147 shares of the company’s stock worth $2,637,000 after purchasing an additional 620 shares during the period. Quantbot Technologies LP acquired a new stake in shares of LivaNova during the first quarter worth $994,000. Headlands Technologies LLC lifted its holdings in shares of LivaNova by 287.3% during the first quarter. Headlands Technologies LLC now owns 6,999 shares of the company’s stock worth $392,000 after purchasing an additional 5,192 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in shares of LivaNova by 4.7% during the first quarter. ProShare Advisors LLC now owns 12,378 shares of the company’s stock worth $692,000 after purchasing an additional 561 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.